A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
NCT06952010
Recruiting
This is a phase 1, first-in-human, open-label, dose-escalation study of XB628, a first-in-class bispecific antibody natural killer (NK) cell engager that targets NK group 2 member A (NKG2A), an inhibitory receptor on NK cells, and programmed cell death-ligand 1 (PD-L1).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Exelixis Clinical Site #1, Hickory, North Carolina +1 locations
Conditions: Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
Register for Updates
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia
NCT03813407
Recruiting
Sodium zirconium cyclosilicate has been shown to be effective and safe in adults for the treatment of hyperkalaemia, and therefore it is expected to be beneficial in children. This study will evaluate the efficacy, safety and tolerability of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in children \<18 years of age. Approximately 140 participants will enter CP at approximately 46 sites in locations including but not limited to Europe and North America for this study. Treatme... Read More
Gender:
ALL
Ages:
Between 0 years and 18 years
Trial Updated:
05/05/2025
Locations: Research Site, Birmingham, Alabama +68 locations
Conditions: Hyperkalaemia
Register for Updates
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647
Recruiting
The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the investigator to benefit from continued treatment with secukinumab, and are unable to obtain the marketed secukinumab formulation.
Gender:
ALL
Ages:
Between 6 years and 100 years
Trial Updated:
05/05/2025
Locations: Providence Medical Foundation, Fullerton, California +166 locations
Conditions: Autoimmunity, Inflammation
Register for Updates
Stellate Ganglion Block for PTSD
NCT05169190
Recruiting
Posttraumatic Stress Disorder (PTSD) is a debilitating condition that affects about 15% of Veterans. Current treatments for Veterans with PTSD include medications and psychological therapies that help to process and desensitize to traumatic events. While effective for many, these treatments do not work for all patients, and many may refuse them. Stellate Ganglion Block (SGB), established to treat pain and other conditions, has shown promise for PTSD: early small studies show it may work fast and... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/05/2025
Locations: VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California +5 locations
Conditions: Post-traumatic Stress Disorder
Register for Updates
Oxalate-Driven Host Responses in Kidney Stone Disease
NCT05417568
Recruiting
This study is looking to understand the role of oxalate on kidney stone development and immunity. This study will enroll healthy participants and participants with calcium oxalate kidney stones (CaOx KS). Participants will be in this study for about 3 weeks, consume controlled diets, and provide blood and urine specimens.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
05/05/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Kidney Stones
Register for Updates
A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity
NCT05621616
Recruiting
People with neurogenic detrusor overactivity (NDO) have poor bladder control because of how their nerves to the bladder are wired. This can cause high pressure in the bladder, causing it to leak urine by accident (incontinence). Mirabegron has already been approved for adults with bladder problems and for children 3 years and older. This study will learn if mirabegron can help young children with NDO. The children will be from 6 months to up to 3 years old. The main aim of this study is to lear... Read More
Gender:
ALL
Ages:
Between 6 months and 3 years
Trial Updated:
05/05/2025
Locations: Stanford Hospital, Palo Alto, California +10 locations
Conditions: Neurogenic Detrusor Overactivity
Register for Updates
Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC
NCT05768347
Recruiting
The purpose of the study is to evaluate the feasibility, safety and tolerability of intravesical adoptive cell therapy using TIL (tumor infiltrating lymphocytes) in participants with urothelial cell carcinoma (UCC) non-muscle invasive bladder cancer (NMIBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma
Register for Updates
Vagus Nerve Stimulation(VNS) As Treatment For Fibromyalgia Patients
NCT06009159
Recruiting
Fibromyalgia (FM) is a syndrome with clinical symptoms involving multiple systems. The efficacy of current treatments is inadequate, and more alternative modalities are needed for the management of FM patients. The parasympathetic vagus nerve innervates and integrates sensory, motor, and autonomic systems and has been suggested to play a role in pain modulation. The role of vagus nerve stimulation (VNS) as a treatment option for FM patients is yet to be investigated. The investigators propose to... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/05/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Fibromyalgia
Register for Updates
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972
Recruiting
The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
05/05/2025
Locations: Pinnacle Research Group Llc, Anniston, Alabama +62 locations
Conditions: Systemic Lupus Erythematosus
Register for Updates
Durometer for Measuring Uterine Tone
NCT06284421
Recruiting
This study will evaluate the use of a durometer to measure uterine tone in parturients undergoing cesarean delivery.
Gender:
FEMALE
Ages:
Between 18 years and 50 years
Trial Updated:
05/05/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Uterine Tone Disorders, Cesarean Section Complications
Register for Updates
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
NCT06355531
Recruiting
PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
05/05/2025
Locations: The Neurology Center of Southern California - Carlsbad, Carlsbad, California +41 locations
Conditions: Progressive Supranuclear Palsy
Register for Updates
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202
Recruiting
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Allervie Clinical Research - Cullman, Cullman, Alabama +149 locations
Conditions: Chronic Spontaneous Urticaria
Register for Updates